High impact
Levoleucovorin (Khapzory) (CPB 0889, reviewed 2025-12-04)
Aetna·Effective Dec 4, 2025
HCPCS J9250 is officially defined as "Methotrexate sodium, 5 mg." HCPCS J9250 is referenced in 1 tracked payer policy change from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9250 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.